SCHEMBL30142244

SCHEMBL30142244

O=C(NCCCO)c1n[nH]c2c(F)cccc12

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ WNT1 P04628 5/20 0.49
▸ DYRK1A Q13627 5/20 0.49
▸ HTR1A P08908 3/20 0.47
▸ DRD2 P14416 3/20 0.47
▸ HTR2A P28223 3/20 0.47
▸ RAB9A P51151 4/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HTR2C P28335 1/20 0.43
▸ HRH1 P35367 1/20 0.43
▸ HDAC3 O15379 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ ALPL P05186 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30142245 1.00 WNT1 (0.49) WNT1DYRK1AHTR1ADRD2HTR2A
SCHEMBL30142319 0.92 RAB9A (0.48) WNT1DYRK1AHTR1ADRD2HTR2A
SCHEMBL30142268 0.88 WNT1 (0.64) WNT1DYRK1AHTR1ADRD2HTR2A
SCHEMBL30142248 0.83 RAB9A (0.43) WNT1DYRK1AHTR1ADRD2HTR2A
SCHEMBL30142265 0.83 RAB9A (0.43) WNT1DYRK1AHTR1ADRD2HTR2A
SCHEMBL30142240 0.83 SMN1; SMN2 (0.44) WNT1DYRK1AHTR1ADRD2HTR2A
SCHEMBL30142246 0.82 WNT1 (0.62) WNT1DYRK1AHTR1ADRD2HTR2A
SCHEMBL30142289 0.81 DYRK1A (0.41) WNT1DYRK1AHTR1ADRD2HTR2A
SCHEMBL30142384 0.80 DYRK1A (0.51) WNT1DYRK1ARAB9ASMN1; SMN2NPC1
SCHEMBL30142285 0.78 YTHDC1 (0.59) WNT1DYRK1ARAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388964-A1 (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS HIBERCELL, INC. 2022-12-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220388964-A1 (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS EIF2AK4, GCN1, GNAI2 WNT1 2112/4885DYRK1A 3529/4885HTR1A 3990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback